CCA
VNRX icon

Clearwater Capital Advisors’s VolitionRx Ltd VNRX Stock Holding History

Clearwater Capital Advisors’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50
Closed -$2K – 545
2018
Q1 		$2K Buy
+50
New +$2.92K ﹤0.01% 603

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return

Clearwater Capital Advisors's VNRX Position: Q2 2018 in Review

Clearwater Capital Advisors sold out of VolitionRx Ltd (VNRX) in Q2 2018, closing a stake of 50 shares — an estimated $2K sold.

Clearwater Capital Advisors first reported a position in VNRX in Q1 2018 and held it in 1 quarter. The position peaked at $2K in Q1 2018. 24 funds tracked by Wall St. Rank hold VNRX as of Q2 2018.

  • Clearwater Capital Advisors reported no remaining VolitionRx Ltd position as of Q2 2018 after selling out during the quarter.
  • Clearwater Capital Advisors sold 50 VolitionRx Ltd shares in Q2 2018, an estimated $2K.
  • Clearwater Capital Advisors first reported a position in VolitionRx Ltd in Q1 2018 and held it in 1 quarter.
  • Clearwater Capital Advisors's VolitionRx Ltd position peaked at $2K in Q1 2018.
  • 24 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2018.

Based on Clearwater Capital Advisors's 13F filing for Q2 2018, filed 16 Aug 2018.